Lace John W, Merz Zachary C, Galioto Rachel
Neurological Institute, Section of Neuropsychology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
LeBauer Department of Neurology, The Moses H. Cone Memorial Hospital, Greensboro, NC 27401, USA.
Neurol Int. 2021 Sep 23;13(4):477-486. doi: 10.3390/neurolint13040047.
Within the neuropsychological assessment, clinicians are responsible for ensuring the validity of obtained cognitive data. As such, increased attention is being paid to performance validity in patients with multiple sclerosis (pwMS). Experts have proposed batteries of neuropsychological tests for use in this population, though none contain recommendations for standalone performance validity tests (PVTs). The California Verbal Learning Test, Second Edition (CVLT-II) and Brief Visuospatial Memory Test, Revised (BVMT-R)-both of which are included in the aforementioned recommended neuropsychological batteries-include previously validated embedded PVTs (which offer some advantages, including expedience and reduced costs), with no prior work exploring their utility in pwMS. The purpose of the present study was to determine the potential clinical utility of embedded PVTs to detect the signal of non-credibility as operationally defined by below criterion standalone PVT performance. One hundred thirty-three (133) patients ( age = 48.28; 76.7% women; 85.0% White) with MS were referred for neuropsychological assessment at a large, Midwestern academic medical center. Patients were placed into "credible" ( = 100) or "noncredible" ( = 33) groups based on a standalone PVT criterion. Classification statistics for four CVLT-II and BVMT-R PVTs of interest in isolation were poor (AUCs = 0.58-0.62). Several arithmetic and logistic regression-derived multivariate formulas were calculated, all of which similarly demonstrated poor discriminability (AUCs = 0.61-0.64). Although embedded PVTs may arguably maximize efficiency and minimize test burden in pwMS, common ones in the CVLT-II and BVMT-R may not be psychometrically appropriate, sufficiently sensitive, nor substitutable for standalone PVTs in this population. Clinical neuropsychologists who evaluate such patients are encouraged to include standalone PVTs in their assessment batteries to ensure that clinical care conclusions drawn from neuropsychological data are valid.
在神经心理学评估中,临床医生负责确保所获认知数据的有效性。因此,多发性硬化症患者(pwMS)的表现有效性受到了更多关注。专家们已经提出了一系列用于该人群的神经心理学测试组合,不过没有一个包含独立表现有效性测试(PVT)的建议。《加利福尼亚言语学习测试第二版》(CVLT-II)和《修订版简短视觉空间记忆测试》(BVMT-R)——这两者都包含在上述推荐的神经心理学测试组合中——包含先前已验证的嵌入式PVT(具有一些优势,包括便利性和成本降低),但之前没有研究探索它们在pwMS中的效用。本研究的目的是确定嵌入式PVT在检测低于标准独立PVT表现所定义的不可信信号方面的潜在临床效用。133名患有多发性硬化症的患者(年龄 = 48.28岁;76.7%为女性;85.0%为白人)被转介到中西部一家大型学术医疗中心进行神经心理学评估。根据独立PVT标准,患者被分为“可信”(n = 100)或“不可信”(n = 33)组。单独对四个感兴趣的CVLT-II和BVMT-R PVT进行分类统计时表现不佳(曲线下面积[AUCs]=0.58 - 0.62)。计算了几个算术和逻辑回归推导的多变量公式,所有这些公式同样显示出较差的辨别能力(AUCs = 0.61 - 0.64)。尽管嵌入式PVT在pwMS中可以说是能最大限度地提高效率并最小化测试负担,但CVLT-II和BVMT-R中常见的嵌入式PVT在心理测量学上可能不合适,不够敏感,也不能替代该人群中的独立PVT。鼓励评估此类患者的临床神经心理学家在其评估组合中纳入独立PVT,以确保从神经心理学数据得出的临床护理结论是有效的。